Lv51
1020 积分 2022-11-10 加入
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
1个月前
已完结
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
1个月前
已完结
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
1个月前
已完结
Activation of OX40 Augments Th17 Cytokine Expression and Antigen-Specific Uveitis
1个月前
已完结
Analysis of Single‐Cell Transcriptome and Surface Protein Expression in Ankylosing Spondylitis Identifies OX40‐Positive and Glucocorticoid‐Induced Tumor Necrosis Factor Receptor–Positive Pathogenic Th17 Cells
1个月前
已完结
S2k guideline for the treatment of hidradenitis suppurativa / acne inversa – Short version
1个月前
已完结
Atopic dermatitis
2个月前
已关闭
Atopic dermatitis
2个月前
已关闭
[Chinese expert consensus on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors]
2个月前
已完结
Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme
2个月前
已完结
皖公网安备34019202002308
